• 1. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 2. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837

Comprehensive Overview of 4-Ethoxy-3-fluorobenzonitrile (CAS No. 1156079-46-7): Properties, Applications, and Industry Insights

4-Ethoxy-3-fluorobenzonitrile (CAS No. 1156079-46-7) is a specialized organic compound gaining traction in pharmaceutical and agrochemical research due to its unique structural features. This fluorinated benzonitrile derivative combines an ethoxy group and a fluorine atom at strategic positions, making it a valuable intermediate for synthesizing bioactive molecules. With the rising demand for fluorinated building blocks in drug discovery, this compound has become a focal point for researchers exploring structure-activity relationships (SAR) and metabolic stability enhancement.

The compound's molecular formula, C₉H₈FNO, and its high purity grade (>97%) make it suitable for precision applications. Recent studies highlight its role in developing kinase inhibitors and G-protein-coupled receptor (GPCR) modulators, addressing trending topics like targeted cancer therapies and neurodegenerative disease research. Its lipophilicity (LogP ~2.1) and moderate molecular weight (165.17 g/mol) align with modern Lipinski's Rule of Five criteria for drug-like compounds.

In agrochemical applications, 4-Ethoxy-3-fluorobenzonitrile serves as a precursor for novel crop protection agents, particularly in designing systemic fungicides with improved plant mobility. The fluorine atom enhances binding affinity to biological targets while the ethoxy group influences solubility parameters—a critical consideration for formulation scientists addressing environmental sustainability concerns.

Synthetic routes to this compound typically involve nucleophilic aromatic substitution (SNAr) reactions or palladium-catalyzed cyanation of appropriate halobenzene precursors. Recent innovations in continuous flow chemistry have improved its production efficiency, reducing waste generation—a response to the pharmaceutical industry's growing emphasis on green chemistry principles.

Analytical characterization of CAS No. 1156079-46-7 employs advanced techniques including HPLC-MS for purity assessment and NMR spectroscopy (particularly ¹⁹F-NMR) for structural confirmation. These methods address quality control challenges in high-potency API manufacturing, where even minor impurities can significantly impact biological activity.

The compound's stability profile shows excellent resistance to hydrolytic degradation under physiological pH conditions (pH 2-8), making it suitable for oral drug formulations. This property aligns with current industry focus on improved bioavailability of fluorinated compounds, a frequent search topic among medicinal chemists.

Market analysts note increasing patent filings incorporating 4-Ethoxy-3-fluorobenzonitrile scaffolds, particularly in EGFR inhibitors and BTK signaling pathway modulators. Its commercial availability through major chemical suppliers in milligram to kilogram quantities facilitates both exploratory research and scale-up activities.

From an environmental perspective, the compound's moderate biodegradability and low bioaccumulation potential make it preferable to persistent halogenated analogs, addressing regulatory concerns about PFAS alternatives in industrial applications. Proper handling requires standard laboratory precautions, with SDS documentation available through reputable suppliers.

Future research directions may explore its utility in PET radiopharmaceuticals (given the fluorine-18 isotope compatibility) or as a template for covalent inhibitor design—both areas experiencing exponential growth in pharmaceutical R&D. The compound's versatility ensures its continued relevance as the demand for fluorine-containing pharmacophores expands across therapeutic areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)